The burden of migraine. A review of cost to society.

Richard B. Lipton, W. F. Stewart, M. Von Korff

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Migraine is a common episodic disorder with considerable impact on individuals and society. Migraine occurs with the highest prevalence between the ages of 25 and 55 years, potentially the most productive period of life. Severe migraine can lead to disruption of work, family and social life, the long term consequences of which may affect quality of life. The direct costs of migraine (due to medical care) are small compared with the indirect costs caused by absence from work and reduced productivity. Population-based studies are required to assess incidence, prevalence and distribution of the disease. These studies also reveal that migraine is currently underdiagnosed and undertreated. The cumulative impact of migraine on individuals produces the burden of illness on society. Measuring the severity of migraine is important in understanding the extent of the burden of migraine on the individual and on society. Measures of severity may be useful as predictors of disability and healthcare use. These measures may also be useful in assessing the need for patient care and treatment and help target those more disabled by migraine. Identifying and treating appropriate patients should reduce the impact of migraine on the individual and the burden of migraine on society.

Original languageEnglish (US)
Pages (from-to)215-221
Number of pages7
JournalPharmacoEconomics
Volume6
Issue number3
StatePublished - Sep 1994

Fingerprint

Migraine Disorders
Costs and Cost Analysis
Cost of Illness
Patient Care
Quality of Life
Delivery of Health Care
Incidence

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology

Cite this

Lipton, R. B., Stewart, W. F., & Von Korff, M. (1994). The burden of migraine. A review of cost to society. PharmacoEconomics, 6(3), 215-221.

The burden of migraine. A review of cost to society. / Lipton, Richard B.; Stewart, W. F.; Von Korff, M.

In: PharmacoEconomics, Vol. 6, No. 3, 09.1994, p. 215-221.

Research output: Contribution to journalArticle

Lipton, RB, Stewart, WF & Von Korff, M 1994, 'The burden of migraine. A review of cost to society.', PharmacoEconomics, vol. 6, no. 3, pp. 215-221.
Lipton RB, Stewart WF, Von Korff M. The burden of migraine. A review of cost to society. PharmacoEconomics. 1994 Sep;6(3):215-221.
Lipton, Richard B. ; Stewart, W. F. ; Von Korff, M. / The burden of migraine. A review of cost to society. In: PharmacoEconomics. 1994 ; Vol. 6, No. 3. pp. 215-221.
@article{d4ec48807008453f94197f60f8b06086,
title = "The burden of migraine. A review of cost to society.",
abstract = "Migraine is a common episodic disorder with considerable impact on individuals and society. Migraine occurs with the highest prevalence between the ages of 25 and 55 years, potentially the most productive period of life. Severe migraine can lead to disruption of work, family and social life, the long term consequences of which may affect quality of life. The direct costs of migraine (due to medical care) are small compared with the indirect costs caused by absence from work and reduced productivity. Population-based studies are required to assess incidence, prevalence and distribution of the disease. These studies also reveal that migraine is currently underdiagnosed and undertreated. The cumulative impact of migraine on individuals produces the burden of illness on society. Measuring the severity of migraine is important in understanding the extent of the burden of migraine on the individual and on society. Measures of severity may be useful as predictors of disability and healthcare use. These measures may also be useful in assessing the need for patient care and treatment and help target those more disabled by migraine. Identifying and treating appropriate patients should reduce the impact of migraine on the individual and the burden of migraine on society.",
author = "Lipton, {Richard B.} and Stewart, {W. F.} and {Von Korff}, M.",
year = "1994",
month = "9",
language = "English (US)",
volume = "6",
pages = "215--221",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - The burden of migraine. A review of cost to society.

AU - Lipton, Richard B.

AU - Stewart, W. F.

AU - Von Korff, M.

PY - 1994/9

Y1 - 1994/9

N2 - Migraine is a common episodic disorder with considerable impact on individuals and society. Migraine occurs with the highest prevalence between the ages of 25 and 55 years, potentially the most productive period of life. Severe migraine can lead to disruption of work, family and social life, the long term consequences of which may affect quality of life. The direct costs of migraine (due to medical care) are small compared with the indirect costs caused by absence from work and reduced productivity. Population-based studies are required to assess incidence, prevalence and distribution of the disease. These studies also reveal that migraine is currently underdiagnosed and undertreated. The cumulative impact of migraine on individuals produces the burden of illness on society. Measuring the severity of migraine is important in understanding the extent of the burden of migraine on the individual and on society. Measures of severity may be useful as predictors of disability and healthcare use. These measures may also be useful in assessing the need for patient care and treatment and help target those more disabled by migraine. Identifying and treating appropriate patients should reduce the impact of migraine on the individual and the burden of migraine on society.

AB - Migraine is a common episodic disorder with considerable impact on individuals and society. Migraine occurs with the highest prevalence between the ages of 25 and 55 years, potentially the most productive period of life. Severe migraine can lead to disruption of work, family and social life, the long term consequences of which may affect quality of life. The direct costs of migraine (due to medical care) are small compared with the indirect costs caused by absence from work and reduced productivity. Population-based studies are required to assess incidence, prevalence and distribution of the disease. These studies also reveal that migraine is currently underdiagnosed and undertreated. The cumulative impact of migraine on individuals produces the burden of illness on society. Measuring the severity of migraine is important in understanding the extent of the burden of migraine on the individual and on society. Measures of severity may be useful as predictors of disability and healthcare use. These measures may also be useful in assessing the need for patient care and treatment and help target those more disabled by migraine. Identifying and treating appropriate patients should reduce the impact of migraine on the individual and the burden of migraine on society.

UR - http://www.scopus.com/inward/record.url?scp=0028511136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028511136&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 215

EP - 221

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 3

ER -